Aldesleukin Completed Phase 1 Trials for Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Malignant Lymphomas / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00003243Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
NCT00012207Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00009698Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia
NCT00107354Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
NCT00182650Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
NCT00058045Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer
NCT00020462Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma
NCT00002687Interleukin-2 in Treating Patients With Mycosis Fungoides